Efgartigimod for the Treatment of Guillain-Barré Syndrome

Sponsor
Zhongming Qiu
Study ID
NCT06885762
Phase
PHASE2/PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Guillain-Barre Syndrome (GBS)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • efgartigimod — DRUG
    efgartigimod 20 mg/kg was administered via intravenous infusion on day 1 and day 5 of the treatment period only.

Study Details

The goal of this clinical trial is to evaluating the efficacy and safety of efgartigimod in the treatment of Guillain-Barré Syndrome and exploring the immunological mechanisms of efgartigimod therapy in Guillain-Barré Syndrome. The main questions it aims to answer are: Will efgartigimod improve the symptoms of participants? What medical problems do participants have when using efgartigimod? Participants will: On day 1 and day 5 of the treatment period, drug A was administered intravenously. Keep a diary of their symptoms

Key Dates

Start date
Apr 13, 2025
Status verified
Feb 2025
Primary completion
Jun 30, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment group

Primary Outcome Measure

Guillain-Barré Syndrome Disability Scale (GBS-DS) [ Time Frame: 12 weeks. ]

Central Contacts